# CT-P13 (Infliximab) Subcutaneous Administration by Pre-filled Syringe and Auto-injector in Healthy Subjects

> **NCT03446976** · PHASE1 · COMPLETED · sponsor: **Celltrion** · enrollment: 218 (actual)

## Conditions studied

- Health, Subjective

## Interventions

- **BIOLOGICAL:** CT-P13 SC Auto-injector
- **BIOLOGICAL:** CT-P13 SC Pre-filled Syringe

## Key facts

- **NCT ID:** NCT03446976
- **Lead sponsor:** Celltrion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-21
- **Primary completion:** 2018-07-26
- **Final completion:** 2018-07-26
- **Target enrollment:** 218 (ACTUAL)
- **Last updated:** 2019-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03446976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03446976, "CT-P13 (Infliximab) Subcutaneous Administration by Pre-filled Syringe and Auto-injector in Healthy Subjects". Retrieved via AI Analytics 2026-06-06 from https://api.ai-analytics.org/clinical/NCT03446976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*